2 recruiting, 1 completed. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Post-polycythemia Vera Myelofibrosis (PPV-MF): new trials by email Literature Review of Post-polycythemia Vera Myelofibrosis (PPV-MF) trials Research Report on Post-polycythemia Vera Myelofibrosis (PPV-MF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-11-10 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Bomedemstat - Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 90 | 2017-07-18 | 2024-01-10 |
Primary Myelofibrosis (3) · Blast Crisis (1) · Bone Marrow Neoplasms (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Rare Diseases (1) · Thrombocythemia, Essential (1)
Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Myeloproliferative Disorders (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Carcinogenesis (1) · Cell Transformation, Neoplastic (1) · Chronic Disease (1) · Disease Attributes (1) · Hemorrhagic Disorders (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid (1) · Neoplasms (1)
bomedemstat (1) · ruxolitinib (1)
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (1) · MPN Research Foundation (1) · Novartis Pharmaceuticals (1)
United States (3) · Australia (2) · Germany (2) · Italy (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · France (1) · India (1) · Japan (1) · Malaysia (1)
2018 (1), 2025 (1)